drugset / Trial / NCT04844775
A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults
Phase 1
Completed
68 enrolled
ANRS, Emerging Infectious Diseases
Chelsea and Westminster Hospital, UK · collabEuroVacc Foundation · collabEuropean Commission · collabHenri Mondor University Hospital · collabImperial College London · collabMedical Research Council · collabRecherche Clinique Paris Descartes Necker Cochin Sainte Anne · collabSwiss Government · collabUniversity College London Hospitals · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
EHVA P01 is an international, phase I, prophylactic HIV vaccine trial to evaluate the safety and immunogenicity of HIV Clade C DREP alone and in Combination with a Clade C ENV protein in healthy HIV-uninfected adults.
Timeline
- Start
- 2022-08-05
- Primary completion
- 2024-09-09
- Completion
- 2024-09-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DNA-HIV-PT123 | Vaccine | 4 mg | Intramuscular |
| Subject | DREP-HIV-PT1 | Vaccine | 0.2 mg | Intramuscular |
| Subject | DREP-HIV-PT1 | Vaccine | 1 mg | Intramuscular |
| Background | CN54gp140 | Vaccine | 100 ug | Intramuscular |
| Background | MPLA-L | Other / unclassified | 5 ug | Intramuscular |
Indications
No indication recorded.